Business Wire

CA-ARRCUS

Share
Arrcus Enhances ACE-AI Solution with New Platforms and Functionality to Deliver Lossless Connectivity Fabric for Next-Gen Distributed AI Workloads

Arrcus, the hyperscale networking software company and a leader in core, edge, and multi-cloud routing and switching infrastructure, announces the enhancement of its ACE-AI platform to address the growing demand for unified networking fabric for distributed AI workloads.

As AI workloads become increasingly distributed, driven by economic considerations and application requirements, Arrcus ACE-AI is a platform designed to seamlessly network them across various locations and deliver applications at the edge, with high speed and lossless connectivity. The emerging federated learning model for AI allows multiple entities to collaboratively train a model with decentralized data. Training models may be executed in hyperscale environments while inference models may be executed at the edge for various use cases. Arrcus recognizes the need for a unified networking fabric that interconnects these workloads, regardless of where they may reside. Modern data center applications demand high throughput (400-800Gbps) and ultra-low latency (< 10μs per hop), and Arrcus ACE-AI meets these demands while minimizing CPU overhead.

"The future of AI lies in its ubiquity, and Arrcus has built the industry’s most flexible and intelligent fabric that connects and orchestrates distributed AI workloads,” said Shekar Ayyar, Chairman and CEO of Arrcus. “With the enhanced ACE-AI platform, we are giving enterprises and service providers the power to unlock the full potential of AI, across clouds, data centers, and the edge."

Emerging artificial intelligence, high-performance computing, and storage workloads pose new challenges for large-scale datacenter networking. Arrcus addresses these challenges by supporting new features that build a lossless Ethernet fabric, including RoCEv2, PFC, ECN, ETS, AR, Dynamic Load Balancing, and Global Load Balancing.

One of the significant challenges in achieving high-performance networking for AI workloads is the limitation of traditional TCP/IP stacks at such speeds due to their high CPU overhead. Arrcus addresses this challenge by incorporating RDMA (Remote Direct Memory Access) technology, which offloads transport communication tasks from the CPU to hardware, providing direct memory access for applications without involving the CPU. The second version of RDMA over Converged Ethernet (RoCE-v2) further enhances the protocol with UDP/IP headers with routing.

In addition to these feature enhancements, Arrcus is also pleased to announce support for new industry-leading platforms from Broadcom that are state-of-the-art 800G switching platforms – Tomahawk5, Jericho3, Ramon3 – in partnership with device manufacturers like Ufispace and Edgecore.

"Broadcom is very excited to collaborate with Arrcus to deliver industry-leading switching solutions that are optimized to meet the performance demands of next-generation AI workloads. Together, Arrcus and Broadcom are enabling customers to build high-performance, scalable, and intelligent data center networks,” said Ram Velaga, senior vice president and general manager, Core Switching Group, Broadcom.

Key features that make Arrcus the industry’s leading networking platform for AI:

  • High-Performance Networking for AI: Support for industry-leading hardware with Broadcom switches like Tomahawk5 and Jericho3-AI, RoCEv2, SmartNICs from NVIDIA and Intel, and enabling ultra-low latency (< 10μs per hop) and high throughput (400-800Gbps) required by modern AI applications.
  • Multi-Cloud Cost Optimization: Enhanced FlexMCN with Egress Cost Control (ECC) technology empowers users to analyze, allocate, and dynamically route traffic across clouds for optimal cost efficiency, reducing egress charges by up to 15%.
  • Automated 5G Network Slicing for AI: Integration of SRv6 Mobile User Plane (MUP) and Flex Algo enables automated delivery of AI applications with 5G network slicing, streamlining service deployment and resource allocation.
  • End-to-End Network Visibility with ArcIQ: New ArcIQ capabilities extend real-time network insights to user equipment, providing actionable data for proactive incident management.

With these latest capabilities and dedication to innovation, Arrcus is enabling organizations to break through the limitations of traditional networking and embrace the full potential of distributed AI. The enhanced ACE-AI platform signifies a pivotal step in building the intelligent fabric for the AI-powered future.

Additional Resources

About Arrcus

Arrcus was founded to enhance business efficiency through superior network connectivity. The Arrcus Connected Edge (ACE) platform offers best-in-class networking with the most flexible consumption model at the lowest total cost of ownership. The Arrcus team consists of world-class technologists who have an unparalleled record in shipping industry-leading networking products, complemented by industry thought leaders, operating executives, strategic partners and top-tier VCs. The company is headquartered in San Jose, California, with offices in Bangalore, India, and Tokyo, Japan. For more information, go to www.arrcus.com or follow @arrcusinc.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240226461853/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release

‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye